Trial intelligence / Profile preview

Short-term versus long-term neoadjuvant chemoradiotherapy for middle-lower rectal cancer

ChiCTR-TRC-10001108Phase 4Completed

Sponsor
Peking University Cancer Hospital & Institute
Start
Jan 2010
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of capecitabine in rectal cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 3-year disease-free survival. Started Jan 2010; status: completed.

02

Drugs

capecitabine
03

Conditions

rectal cancer

Beyond the preview

Go deeper on ChiCTR-TRC-10001108.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-TRC-10001108.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call